GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects a multi-blockbuster ...

Chime Biologics, a leading global CDMO that enables its partners' success in biologics, and Waterstone, a reliable partner ...

Entero has signed a binding term sheet in which private biotech Journey is slated to acquire 99% of Entero’s equity, ...

Swiss CDMO Lonza is bulking up its bioconjugation manufacturing digs with two new multicustomer suites and 200 new jobs at ...

CEO Roberto Iacone admitted in an interview that the market remains tough, even for a biotech in the red-hot ADC world. But ...

NextCure is going all in on its preclinical B7-H4-directed antibody-drug conjugate (ADC). | NextCure is going all in on its ...

A team of researchers have applied a novel blood test that can detect early signs of potentially fatal lung damage in cancer ...

As pharmaceutical companies embrace antibody-drug conjugates (ADCs) as a way to treat cancer, drug services providers are ...

Following the clearance of an investigational new drug application from the FDA, a phase 1 trial will examine the novel ...

Based outside Boston, MilliporeSigma was formed after Merck KGaA acquired St. Louis-based Sigma-Aldrich Corp. for $17 billion ...

Press Release: Araris Biotech Publishes Foundational Science Behind its Novel Antibody-Drug Conjugate Platform in ChemBioChem First characterization of its novel conjugation technology for creating ...